SIRS-Lab GmbH Receives CE Approval for Sepsis Test "VYOO" and Unfolds Full Clinical Potential

Published: Dec 03, 2008

JENA, Germany--(BUSINESS WIRE)--SIRS-Lab today announced that the EU regulatory authorities have granted the CE mark for VYOO, a molecular diagnostic test for pathogen detection in sepsis. With VYOO, clinicians can rapidly and reliably identify causative pathogens as well as important antibiotic resistance markers. Therefore VYOO allows for a customized anti-infective therapy in each patient within the critical hours of treatment. The CE mark will accelerate the implementation of VYOO into clinical routine throughout Europe.

Sepsis, a life-threatening systemic infection, is with more than 2 million cases per year the 2nd cause of death in hospitals after cardio-vascular diseases. SIRS-Lab, a leading molecular diagnostic company in the field of sepsis, has released VYOO in 2007. The cutting-edge pathogen detection test provides significant advantages over currently used methods in clinical practice.

In his comments on the CE approval, SIRS-Lab’s CEO PD Dr Stefan Russwurm states: “In important European clinical centers, for example in Paris or Basel, patients already benefit from the therapeutic advantages provided by VYOO. With the CE status, the full potential of this ground-breaking approach to sepsis diagnostics will be realized.”

For SIRS-Lab, the CE approval is an important milestone enabling the company to manufacture VYOO in accordance to ISO 13485 standards and sell it for routine In-vitro diagnostic use (IVD directive 98/79/EC).

For further information, please visit:

Press Room:



SIRS-Lab GmbH Axel Kunz, +49 3641 508 430

Source: SIRS-Lab GmbH

Back to news